MSB 7.69% $1.19 mesoblast limited

Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-158

  1. 16,651 Posts.
    lightbulb Created with Sketch. 2375
    Let's not forget how SI said the Covid-ARDS trial "flew through" the interim analysis, only to be stopped a little later after failing a futility test. And how the MSB investors were crowing it would be stopped early for "overwhelming efficacy"
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.